Oncolys BioPharma Inc. announced that it has received a notice from Transposon Therapeutics Inc. ("Transposon"), licensee of OBP-601 (censavudine, TPN-101), that enrollment has been completed in the Phase IIa, double-blind, placebo-controlled study of OBP-601 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) who have the C9ORF72 repeat expansion mutation. In addition, Transposon has completed enrollment in a Phase IIa, double-blind, placebo-controlled study of TPN-101 in patients with Progressive Supranuclear Palsy (PSP) as well as opened enrollmen t in a Phase IIa, Open Label study of TPN-101 in patients with Aicardi-Goutières Syndrome (AGS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
706 JPY | -0.56% | +1.15% | +24.51% |
1st Jan change | Capi. | |
---|---|---|
+24.51% | 96.38M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Amyotrophic Lateral Sclerosis